Trial Outcomes & Findings for e-HERO: Ending the HIV Epidemic in Rural Oklahoma (NCT NCT05664802)
NCT ID: NCT05664802
Last Updated: 2026-07-27
Results Overview
HIV testing uptake is assessed through the request of an at-home rapid HIV test through the e-HERO platforms.
COMPLETED
NA
72 participants
Assessed at the end of month 3 of the intervention.
2026-07-27
Participant Flow
Recruitment occurred between Dec 1, 2022 and June 19, 2024.
Participant milestones
| Measure |
e-HERO 2.0
The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
|
e-HERO 1.0
e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
|
|---|---|---|
|
Overall Study
STARTED
|
35
|
37
|
|
Overall Study
1-month
|
29
|
29
|
|
Overall Study
COMPLETED
|
20
|
23
|
|
Overall Study
NOT COMPLETED
|
15
|
14
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Baseline characteristics by cohort
| Measure |
e-HERO 2.0
n=35 Participants
The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
|
e-HERO 1.0
n=37 Participants
e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
|
Total
n=72 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
22.54 Years
STANDARD_DEVIATION 3.55 • n=9 Participants
|
23.35 Years
STANDARD_DEVIATION 4.14 • n=27 Participants
|
22.96 Years
STANDARD_DEVIATION 3.86 • n=267 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Sex: Female, Male
Male
|
35 Participants
n=9 Participants
|
37 Participants
n=27 Participants
|
72 Participants
n=267 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
12 Participants
n=9 Participants
|
7 Participants
n=27 Participants
|
19 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=9 Participants
|
2 Participants
n=27 Participants
|
4 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=9 Participants
|
2 Participants
n=27 Participants
|
6 Participants
n=267 Participants
|
|
Race (NIH/OMB)
White
|
16 Participants
n=9 Participants
|
23 Participants
n=27 Participants
|
39 Participants
n=267 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=9 Participants
|
3 Participants
n=27 Participants
|
4 Participants
n=267 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
|
Region of Enrollment
United States
|
35 Participants
n=9 Participants
|
37 Participants
n=27 Participants
|
72 Participants
n=267 Participants
|
PRIMARY outcome
Timeframe: Assessed at the end of month 3 of the intervention.HIV testing uptake is assessed through the request of an at-home rapid HIV test through the e-HERO platforms.
Outcome measures
| Measure |
e-HERO 2.0
n=35 Participants
The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
|
e-HERO 1.0
n=37 Participants
e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
|
|---|---|---|
|
HIV Testing Uptake
|
2 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Baseline, 1 month, and 3 monthsThe outcome scale name is called "Intentions to get tested for HIV", measuring the construct of intention to get tested for HIV in the next 3 months, by asking the 1-item question: "How likely are you to get tested for HIV in the next three months?" The outcome is assessed on a 6-point Likert-type scale.The score range was 1-6, from 1= Extremely unlikely to get tested for HIV to 6=Extremely likely to get tested for HIV. A higher score indicated greater intentions to get tested, which is considered a preferred outcome. There were no subscales.
Outcome measures
| Measure |
e-HERO 2.0
n=35 Participants
The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
|
e-HERO 1.0
n=37 Participants
e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
|
|---|---|---|
|
HIV Testing Intention
Baseline mean
|
3.00 Points
Standard Deviation 1.90
|
3.00 Points
Standard Deviation 1.88
|
|
HIV Testing Intention
Mean at 1-month
|
3.38 Points
Standard Deviation 1.75
|
3.22 Points
Standard Deviation 2.02
|
|
HIV Testing Intention
Mean at 3-month (study end)
|
3.13 Points
Standard Deviation 1.63
|
3.50 Points
Standard Deviation 1.72
|
SECONDARY outcome
Timeframe: Baseline, 1 month, and 3 monthsThe outcome scale name is called "Intentions to get tested for a Sexually Transmitted Infection", measuring the construct of intentions to get a test for an STI in the next 3 months. The outcome was a 1-item question: "How likely are you to get tested for other STIs besides HIV in the next three months?" The answers were assessed on a 6-point Likert-type scale, with a score ranging from 1-6 (1= Extremely unlikely to get tested for an STI to 6=Extremely likely to get tested for an STI). A higher score indicated greater intentions to get tested, which is considered a preferred outcome. There were no subscales.
Outcome measures
| Measure |
e-HERO 2.0
n=35 Participants
The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
|
e-HERO 1.0
n=37 Participants
e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
|
|---|---|---|
|
STI Testing Intention
Baseline mean
|
2.94 Points on 1-6 Likert scale
Standard Deviation 1.81
|
2.72 Points on 1-6 Likert scale
Standard Deviation 1.84
|
|
STI Testing Intention
1-month mean
|
3.19 Points on 1-6 Likert scale
Standard Deviation 1.83
|
3.06 Points on 1-6 Likert scale
Standard Deviation 2.04
|
|
STI Testing Intention
3-month mean (end of study)
|
3.13 Points on 1-6 Likert scale
Standard Deviation 1.71
|
3.28 Points on 1-6 Likert scale
Standard Deviation 1.78
|
Adverse Events
e-HERO 2.0
e-HERO 1.0
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place